Investor Relations Services
Stern IR offers a broad range of investor relations services that often includes working with senior management to achieve key investor relations goals, such as effective positioning, enhancing visibility, improving institutional ownership and sell-side coverage, preparing for financings and IPOs, developing good guidance practices and managing communications around M&A, binary events and other strategic issues.
Since our inception, we have worked with more than 200 biotechnology and pharmaceutical companies, and we represent public, private, and pre-IPO companies in all stages of development and in a wide range of clinical indications. Stern Investor Relations is based in New York City.
The Stern Investor Relations Approach
Our ultimate goal is to help each client realize a valuation that best reflects the company's assets and the internal value of the company through favorable interactions with the investment community.
Investor Relations Clients
- Acceleron Pharma, Inc.
- Acorda Therapeutics Inc.
- Alkermes, Inc.
- Alnylam Pharmaceuticals, Inc.
- AMAG Pharmaceuticals, Inc.
- BioSpecifics Technologies Corp.
- Curis, Inc.
- Interleukin Genetics, Inc.
- ImmunoGen, Inc.
- Ironwood Pharmaceuticals, Inc.
- Millennium: The Takeda Oncology Company
